Gabapentin 600 mg (8744103601 Gabapentin 600 mg)
Gabapentin Tablet
Product Images NDC 87441-036
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 87441-036). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Unit Dose Solutions, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Equation (Equation)
This formula calculates the estimated hemoglobin level using the age and weight of the patient, as well as the serum creatinine level. The formula takes into account different adjustments for female patients.*
Fig1 (Fig1)
Fig2 (Fig2)
This information is about a pain study evaluating mean pain scores over a 3-week dose titration period followed by a 4-week fixed dose period. The study includes a placebo group and two different doses of gabapentin (1800 mg/day and 2400 mg/day). Data is collected at baseline and weekly intervals throughout the study.*
Fig3 (Fig3)
This text contains numerical data related to the proportion of responders (patients with a 50% reduction in pain score) in controlled studies related to post-herpetic neuralgia (PHN). The information is presented in a chart format, depicting percentages of responders at different levels of pain reduction. Study 1 and Study 2 are referenced along with placebo (PBO) and doses of GBP (potentially a medication) at 3600mg and 1800mg. The significance levels of *p<0.01 and *+p<0.001 are also mentioned in the text.*
Figure 4 (Fig4)
Molecula Formula Gabapentin (Structure)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
